Journal of Clinical Oncology, Vol 16, 56-62, Copyright © 1998 by American Society of Clinical Oncology

ARTICLES

Phase I study of bryostatin 1 in patients with relapsed non-Hodgkin's lymphoma and chronic lymphocytic leukemia

ML Varterasian, RM Mohammad, DS Eilender, K Hulburd, DH Rodriguez, PA Pemberton, JM Pluda, MD Dan, GR Pettit, BD Chen and AM Al-Katib
Karmanos Cancer Institute and Wayne State University, Detroit, MI, USA. varterasian@oncgate.roc.wayne.edu

PURPOSE: To define, in a phase I study in relapsed non-Hodgkin's lymphoma (NHL) and chronic lymphocytic leukemia (CLL), the maximum- tolerated dose (MTD), major toxicities, and possible antitumor activity of bryostatin 1, a macrocyclic lactone. PATIENTS AND METHODS: Bryostatin 1 was delivered by 72-hour continuous infusion every 2 weeks to patients with relapsed NHL or CLL, at doses that ranged from 12 microg/m2 to 180 microg/m2 per course. Correlative investigations included evaluations of total protein kinase C (PKC) in peripheral blood and lymphoid differentiation in patient tumor tissue. RESULTS: Twenty-nine patients were treated, including three patients with CLL and 26 with NHL. Generalized myalgia was the dose-limiting toxicity (DLT) and occurred in two of three patients treated with bryostatin 1 at 180 microg/m2 per course. Myalgias were dose-related and cumulative, and often started in the thighs and calves, improved with activity, were somewhat responsive to analgesics, and often took weeks to resolve once taken off study. Six patients were treated at the MTD of 120 microg/m2 per course. Myalgia, headache, and fatigue were common. Hematologic toxicity was uncommon. Total cumulative doses of bryostatin 1 up to 1,134 microg/m2 have been administered without untoward toxicity. Eleven patients achieved stable disease for 2 to 19 months. An in vitro assay for total PKC evaluation in patient peripheral-blood samples demonstrated activation within the first 2 hours with subsequent downregulation by 24 hours, which was maintained throughout the duration of the 72-hour infusion. CONCLUSION: This phase I study defined the MTD and recommended phase II dose of bryostatin 1, when administered over 72 hours every 2 weeks, to be 120 microg/m2 (40 microg/m2/d for 3 days). Generalized myalgia was the DLT. Future studies will define the precise activity of bryostatin 1 in subsets of patients with lymphoproliferative malignancies and its efficacy in combination with other agents.

This article has been cited by other articles:

				G. K. Schwartz and M. A. Shah Targeting the Cell Cycle: A New Approach to Cancer Therapy J. Clin. Oncol., December 20, 2005; 23(36): 9408 - 9421. [Abstract] [Full Text] [PDF]

				W.-C. Chou, C. Jie, A. A. Kenedy, R. J. Jones, M. A. Trush, and C. V. Dang Role of NADPH oxidase in arsenic-induced reactive oxygen species formation and cytotoxicity in myeloid leukemia cells PNAS, March 30, 2004; 101(13): 4578 - 4583. [Abstract] [Full Text] [PDF]

				A. Dowlati, H. M. Lazarus, P. Hartman, J. W. Jacobberger, C. Whitacre, S. L. Gerson, P. Ksenich, B. W. Cooper, P. S. Frisa, M. Gottlieb, et al. Phase I and Correlative Study of Combination Bryostatin 1 and Vincristine in Relapsed B-Cell Malignancies Clin. Cancer Res., December 1, 2003; 9(16): 5929 - 5935. [Abstract] [Full Text] [PDF]

				T. E. Battle and D. A. Frank STAT1 mediates differentiation of chronic lymphocytic leukemia cells in response to Bryostatin 1 Blood, October 15, 2003; 102(8): 3016 - 3024. [Abstract] [Full Text] [PDF]

				C. S. Stevenson, E. A. Capper, A. K. Roshak, B. Marquez, C. Eichman, J. R. Jackson, M. Mattern, W. H. Gerwick, R. S. Jacobs, and L. A. Marshall The Identification and Characterization of the Marine Natural Product Scytonemin as a Novel Antiproliferative Pharmacophore J. Pharmacol. Exp. Ther., November 1, 2002; 303(2): 858 - 866. [Abstract] [Full Text] [PDF]

				L. H. Cragg, M. Andreeff, E. Feldman, J. Roberts, A. Murgo, M. Winning, M. B. Tombes, G. Roboz, L. Kramer, and S. Grant Phase I Trial and Correlative Laboratory Studies of Bryostatin 1 (NSC 339555) and High-Dose 1-B-D-Arabinofuranosylcytosine in Patients with Refractory Acute Leukemia Clin. Cancer Res., July 1, 2002; 8(7): 2123 - 2133. [Abstract] [Full Text] [PDF]

				M. W. Otieno, C. Banura, E. Katongole-Mbidde, J. L. Johnson, M. Ghannoum, A. Dowlati, R. Renne, E. Arts, C. Whalen, M. M. Lederman, et al. Therapeutic Challenges of AIDS-Related Non-Hodgkin's Lymphoma in the United States and East Africa J Natl Cancer Inst, May 15, 2002; 94(10): 718 - 732. [Abstract] [Full Text] [PDF]

				J. A. Vrana and S. Grant Synergistic induction of apoptosis in human leukemia cells (U937) exposed to bryostatin 1 and the proteasome inhibitor lactacystin involves dysregulation of the PKC/MAPK cascade Blood, April 1, 2001; 97(7): 2105 - 2114. [Abstract] [Full Text] [PDF]

				J. A. Zonder, A. F. Shields, M. Zalupski, R. Chaplen, L. K. Heilbrun, P. Arlauskas, and P. A. Philip A Phase II Trial of Bryostatin 1 in the Treatment of Metastatic Colorectal Cancer Clin. Cancer Res., January 1, 2001; 7(1): 38 - 42. [Abstract] [Full Text]

				I. Ahmad, A. M. Al-Katib, F. W. J. Beck, and R. M. Mohammad Sequential Treatment of a Resistant Chronic Lymphocytic Leukemia Patient with Bryostatin 1 Followed by 2-Chlorodeoxyadenosine: Case Report Clin. Cancer Res., April 1, 2000; 6(4): 1328 - 1332. [Abstract] [Full Text]

				M. L. Varterasian, R. M. Mohammad, M. S. Shurafa, K. Hulburd, P. A. Pemberton, D. H. Rodriguez, V. Spadoni, D. S. Eilender, A. Murgo, N. Wall, et al. Phase II Trial of Bryostatin 1 in Patients with Relapsed Low-Grade Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia Clin. Cancer Res., March 1, 2000; 6(3): 825 - 828. [Abstract] [Full Text]

				S. Weitman, A.-M. Langevin, R. L. Berkow, P. J. Thomas, C. A. Hurwitz, A. S. Kraft, R. L. Dubowy, D. L. Smith, and M. Bernstein A Phase I Trial of Bryostatin-1 in Children with Refractory Solid Tumors: A Pediatric Oncology Group Study Clin. Cancer Res., September 1, 1999; 5(9): 2344 - 2348. [Abstract] [Full Text] [PDF]